SecBot SecBot
8-K ·Filed Nov 4, 2026

ARDT

Ardent Health, Inc.
BULLISH
Impact 5/10
Horizonweeks Processed13d 1h ago SEC0001628280-26-070163
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised Adjusted EBITDA guidance midpoint signals improving operational momentum and cost discipline. Monitor the Q4 earnings call for updates on IMPACT savings trajectory, the Kansas hospital divestiture closing, and any impact from healthcare policy changes (OBBBA) on 2027 outlook.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$15.90
T+0 close · Nov 4, 2026 · via day close
Latest settled
+11.20%
T+5 · $17.68 · next T+20 in 17d
Vs SPY
+7.90%
α at T+5
Latest observation
+13.28%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $15.90entry
  2. T+1 · 11d ago +8.80%α +8.49% · $17.30
  3. T+5 · 5d ago +11.20%α +7.90% · $17.68
  4. T+8 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ardent Health reported Q3 2026 revenue of $1.625B (+3.1% YoY) and GAAP diluted EPS of $0.31, compared to a net loss of $0.17 per share in Q3 2025. The company raised its full-year 2026 Adjusted EBITDA guidance midpoint by 1.5% to $500-$535 million, while reaffirming revenue guidance of $6.4B-$6.7B. Adjusted EBITDA was $138M, up from $45M in the prior year quarter, driven by IMPACT program savings and volume improvement.

Key Financial Metrics

EPS
$0.31
est $0.24 · +29.2%
Revenue
$1.6B
est $1.6B · +1.6% · +3.1% YoY
Rating
beat
Guidance
$6,400M-$6,700M
raised

Key Facts

  • Q3 2026 total revenue $1.625B, up 3.1% YoY from $1.577B
  • GAAP diluted EPS $0.31 vs $(0.17) in Q3 2025
  • Adjusted EBITDA $138M vs $45M in Q3 2025, margin expanded to 8.5% from 2.9%
  • Full-year 2026 Adjusted EBITDA guidance raised to $500-$535M from $485-$535M
  • Revenue guidance reaffirmed at $6.4B-$6.7B
  • Adjusted admissions grew 2.9% YoY, accelerating from 2.5% in Q2 2026
  • SWB expense declined 4% YoY, reflecting IMPACT program savings
  • Board authorized $25M increase to share repurchase program; $48M remaining
  • Cash and cash equivalents $766M, lease-adjusted net leverage 2.5x
  • Agreement to transition full ownership of Kansas hospital to JV partner

Financial Impact

Adjusted EBITDA guidance midpoint raised by $7.5M (1.5%); Q3 Adjusted EBITDA $138M vs $45M in prior year

revenueepsadjusted EBITDAguidance

Risk Factors

  • Total surgeries declined 1.9% YoY, with inpatient surgeries down 5.0%
  • Net patient service revenue per adjusted admission grew only 0.7% YoY
  • Revenue growth of 3.1% YoY is decelerating from 7.0% in Q1 2026
  • Enterprise restructuring costs of $5.4M and ERP conversion costs of $5.9M in Q3
  • Healthcare policy uncertainty including potential Medicaid changes under OBBBA

Market Snapshot

Exchange
NYSE
Sector
Services-General Medical & Surgical Hospitals, NEC
Analyst Consensus
63% bullish (19 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-070163
Document: ardt-20261104.htm0001628280-26-070163
Document: 0001628280-26-070163-index-headers.html0001628280-26-070163
Document: 0001628280-26-070163-index.html0001628280-26-070163
Document: 0001628280-26-070163.txt0001628280-26-070163
8-K Data (Synthetic)0001628280-26-070163

Track record

13 reports on ARDT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +64.65% at T+60 after the Aug 15, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 17, 2026today 424B5 Bearish 5/10 Entry $15.00 Now $17.75 −18.33% settles Nov 25
  2. Nov 12, 20265d ago 8-K Bullish 5/10 Entry $17.80 Now $17.75 −0.28% settles Nov 20
  3. Nov 4, 202613d ago 8-K Bullish 5/10 Viewing Entry $15.90 to $17.68 Now $17.75 +11.64% ▲ +11.20% +7.90% vs SPY
  4. Nov 4, 202613d ago Institutional Cluster Neutral 3/10 Entry $12.99 to $18.19 Now $17.75 +36.64% ▲ +40.03% +40.94% vs SPY
  5. Oct 23, 202625d ago 8-K Bearish 5/10 Entry $12.18 to $12.03 Now $17.75 −45.73% ▲ +1.23% −0.03% vs SPY
  6. Aug 20, 202612w ago 144 Neutral 2/10 Entry $10.99 to $10.96 Now $17.75 +61.51% ▼ −0.27% −0.75% vs SPY
  7. Aug 15, 202613w ago Institutional Cluster Bullish 5/10 Entry $10.89 to $11.25 Now $17.75 +62.99% ▲ +3.31% +4.50% vs SPY
  8. Jun 30, 202620w ago 8-K Neutral 3/10 Entry $10.13 to $10.82 Now $17.75 +75.22% ▲ +6.81% +6.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $9.67 to $9.08 Now $17.75 +83.56% ▼ −6.10% −6.54% vs SPY
  10. Jun 2, 202624w ago 8-K Mixed 5/10 Entry $7.83 to $9.32 Now $17.75 +126.69% ▲ +19.03% +22.85% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026